Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 39 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02697058 | Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer | completed | Phase 2 | 84 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 205 | Bristol-Myers SquibbINDUSTRY | 11 | Jul 23, 2024 | clinicaltrials |
| NCT06513455 | Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 132 | Harbin Medical UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT02352337 | First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem(PANOPTIMOX) | completed | Phase 2 | 276 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06387810 | Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer(undetermined) | unknown | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02827201 | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine(FIRGEMAX) | completed | Phase 2 | 127 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06491472 | Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer | recruiting | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06454448 | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06359275 | PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients | recruiting | Phase 2 | 81 | Fudan UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03077685 | Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 54 | NanOlogy, LLCINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT05518071 | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1(FLUOPANC) | completed | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT01580397 | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | completed | Phase 2 | 15 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06018896 | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer(PTCA199-4) | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT05116917 | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.(INFLUENCE) | terminated | Phase 2 | 19 | Herlev HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06429904 | Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 31 | Peking Union Medical College HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX(SLC-0111-17-01) | terminated | Phase 1 / Phase 2 | 6 | British Columbia Cancer AgencyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT06427460 | Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) | recruiting | Phase 2 | 67 | Changhai HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT04698915 | Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | terminated | Phase 2 | 177 | Galera Therapeutics, Inc.INDUSTRY | 4 | May 21, 2024 | clinicaltrials |
| NCT06422156 | SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer(Nim-PC-28) | unknown | Phase 2 | 73 | Peking University Third HospitalOTHER | 0 | May 20, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04672005 | Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer | unknown | Phase 2 | 30 | Lyudmyla BerimOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | not yet recruiting | Phase 2 / Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03351296 | Two Chemotherapy Regimens Plus or Minus Bevacizumab(BETTER2) | active not recruiting | Phase 2 | 140 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06329947 | A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD | not yet recruiting | Phase 2 | 37 | Rui-hua Xu, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06404840 | Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06405685 | Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04090463 | IORT on Borderline Resectable Pancreatic Cancer(PancFORT) | suspended | Phase 2 | 100 | Universita di VeronaOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | terminated | Phase 2 | 6 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06078787 | Olaparib in PALB2 Advanced Pancreatic Cancer(PALBOLA) | unknown | Phase 2 | 16 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03146962 | High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies | completed | Phase 2 | 61 | Weill Medical College of Cornell UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04371224 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer(NaliCap) | unknown | Phase 2 | 200 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04447092 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | unknown | Phase 2 | 77 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03848182 | Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer | terminated | Phase 2 | 10 | Albert Einstein College of MedicineOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06233864 | A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 0 | Apr 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2024source: clinicaltrials